Flanagan Presents at Cell & Gene Meeting on the Mesa 2021

Mr. Flanagan presented at the Cell Gene Meeting at the Mesa Conference October 12, 2021 where he presented the global unmet medical need associated with lumbar disc degeneration, DiscGenics’s new product candidate, IDCT (rebonuputemcel), and the solutions it presents compared to traditional treatments.

In this presentation, Mr. Flanagan outlines the unmet medical need associated with lumbar disc degeneration, or degenerative disc disease (DDD), which affects more than 250 million individuals worldwide every year. DDD is a leading cause of disability worldwide, costs more than $100B per year in the U.S. alone, and is the primary reason for non-cancer opioid prescriptions.

He provides an overview of IDCT (rebonuputemcel), which is an allogeneic injectable cell therapy in development for lumbar DDD. IDCT is a mixture of live discogenic progenitor cells and a viscous carrier. The active ingredient (Drug Substance) of IDCT is a live cell population known as Discogenic cells derived from adult intervertebral disc tissue. It’s delivered non-invasively into the center of the intervertebral disc using a fluoroscopic guidance in procedures similar to discography and intradiscal steroid injections.

In Mr. Flanagan’s conclusion, he outlines the potential of IDCT to provide a solution for lumbar DDD, highlights the strong preclinical bioactivity and safety data, provides updates on two ongoing robust clinical trials in the US and Japan, and touches on DiscGenics’s commercial GMP manufacturing scale-up efforts to meet regulatory requirements and market size.